Evidence map›Paper›PMID 38853208›Full record

ArticleInsights into imaging2024

Unlocking the potential: T1-weighed MRI as a powerful predictor of levodopa response in Parkinson's disease.

Junyi Yan, Xufang Luo, Jiahang Xu, Dongsheng Li, Lili Qiu, Dianyou Li, Peng Cao, Chencheng Zhang

Abstract read
In one paragraph

Article in Insights into imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junyi YanDepartment of Neurosurgery, Clinical Neuroscience Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin 2nd Road 197th, 200025, Shanghai, China.
Xufang LuoMicrosoft Research, Unit 4301-4304 AI Tower, No.701 Yunjin Road, 200232, Shanghai, China. xufluo@microsoft.com.
Jiahang XuMicrosoft Research, Unit 4301-4304 AI Tower, No.701 Yunjin Road, 200232, Shanghai, China.
Dongsheng LiMicrosoft Research, Unit 4301-4304 AI Tower, No.701 Yunjin Road, 200232, Shanghai, China.
Lili QiuMicrosoft Research, Unit 4301-4304 AI Tower, No.701 Yunjin Road, 200232, Shanghai, China.
Dianyou LiDepartment of Neurosurgery, Center for Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Peng CaoDepartment of Diagnostic Radiology, The University of Hong Kong Hong Kong SAR, Hong Kong, China.
Chencheng ZhangDepartment of Neurosurgery, Clinical Neuroscience Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin 2nd Road 197th, 200025, Shanghai, China. i@cczhang.org.ORCID http://orcid.org/0000-0003-4472-4134

Funding

National Natural Science Foundation of China 82101547
6 · The paper itself

Abstract

backgroundThe efficacy of levodopa, the most crucial metric for Parkinson's disease diagnosis and treatment, is traditionally gauged through the levodopa challenge test, which lacks a predictive model. This study aims to probe the predictive power of T1-weighted MRI, the most accessible modality for levodopa response.

methodsThis retrospective study used two datasets: from the Parkinson's Progression Markers Initiative (219 records) and the external clinical dataset from Ruijin Hospital (217 records). A novel feature extraction method using MedicalNet, a pre-trained deep learning network, along with three previous approaches was applied. Three machine learning models were trained and tested on the PPMI dataset and included clinical features, imaging features, and their union set, using the area under the curve (AUC) as the metric. The most significant brain regions were visualized. The external clinical dataset was further evaluated using trained models. A paired one-tailed t-test was performed between the two sets; statistical significance was set at p < 0.001.

resultsFor 46 test set records (mean age, 62 ± 9 years, 28 men), MedicalNet-extracted features demonstrated a consistent improvement in all three machine learning models (SVM 0.83 ± 0.01 versus 0.73 ± 0.01, XgBoost 0.80 ± 0.04 versus 0.74 ± 0.02, MLP 0.80 ± 0.03 versus 0.70 ± 0.07, p < 0.001). Both feature sets were validated on the clinical dataset using SVM, where MedicalNet features alone achieved an AUC of 0.64 ± 0.03. Key responsible brain regions were visualized.

conclusionThe T1-weighed MRI features were more robust and generalizable than the clinical features in prediction; their combination provided the best results. T1-weighed MRI provided insights on specific regions responsible for levodopa response prediction. CRITICAL RELEVANCE STATEMENT: This study demonstrated that T1w MRI features extracted by a deep learning model have the potential to predict the levodopa response of PD patients and are more robust than widely used clinical information, which might help in determining treatment strategy. KEY POINTS: This study investigated the predictive value of T1w features for levodopa response. MedicalNet extractor outperformed all other previously published methods with key region visualization. T1w features are more effective than clinical information in levodopa response prediction.

Indexed as

Levodopa responseMachine learningMagnetic resonance imagingParkinson’s disease

Identifiers

PMID38853208
PMCPMC11162980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.